FIG 2.

Flow cytometry evaluation of CD22 expression in three patients pretreatment (left column) and post-treatment (right column) with InO. The CD22 site density shown reflects that of the entire blast population, irrespective of percentage of CD22 positivity. (A) Partial CD22 expression pre-InO, which is further decreased post-InO. (B) Uniformly positive expression of CD22 pre-InO, with partial/bimodal expression of CD22 post-InO. (C) CD22 expression ranging from moderate to dim pre-InO with diminished CD22 expression post-InO (KMT2A-rearrangment with subsequent lineage switch to acute myeloid leukemia after CD19-directed therapy). InO, inotuzumab ozogamicin.